The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.
CP-MGD-013-01: A Phase
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in bo
This partially randomized phase II trial studies
how well brentuximab vedotin or crizotinib and combination chemotherapy works
in treating patients with newly diagnosed stage II-IV anaplastic large cell
lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can
block cancer grow
This pilot clinical trial studies how rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation (CD)20-positive post-transplant lymphoproliferative disorder. Monoclonal antibodi
To learn more about available lymphoma clinical trials, contact us at firstname.lastname@example.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2019 Cincinnati Children's Hospital Medical Center. All rights reserved.